That's great news! I've also been following the Dravet Syndrome research, and there are some very promising developments.

One exciting treatment is Zorevunersen, an antisense oligonucleotide, which has shown sustained seizure reductions and improvements in behavior, cognition, and quality of life in patients for up to 4 years. In early trials, some patients even experienced up to a 90% reduction in seizures! You can read more about it at emperorstudy.com.

There's also gene replacement therapy that has shown long-term symptom relief in preclinical studies. Other options being explored are Soticlestat, Responsive Neurostimulation (RNS), and LM22A-4. It's a really hopeful time for Dravet Syndrome research.